Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
These should reach 150p on this data alone. They are in discussions with potential partners.
#gdr
Investor relations reply when asked if CE could come sooner.
The description of the 10 days in the agreements is not as specific as to answer that question. The latest is 14th, but it could be earlier.
Regards,
GDR official rns for CE certification & distribution deals on the way!
No stopping this now, everyone wants in before the weekend as news likely to land early next week
Sat at only £36m mcap with £9.9m in cash - huge rise on way here similar to NCYT
This will rise all this week. 150p very soon imo
#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.
#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.
#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.
WORLD LEADER.... 4d ridiculously undervalued...
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.
Just took advantage of dip and bought some more at 82p.
Quick summary of what's at stake on A2 drill spudding in December by mynameiskhan;
There are five sand zones;
Sand A & B : CoS = 100% (FinCapp Broker Report) and has big target of 360 BCF and NPV of $500m = 44p per share (net)
Sand C: It was interpreted thin sand in original well but data shows thick zone at updip location. Sand C has potential of 164 BCF gas and CoS 64%
Sand M : It was water wet but very small potential of nearly 20 bcf or so. (Very small and insignificant)
Sand O (Deep + Footwall) : Original drill didn't test deep target in Sand O, Appraisal well will be the first well to test sand O. However, seismic shows same attributes as shown in Sand A & B.
Sand O (Deep) has 37% COS & 358 BCF gas potential, while Sand O footwall has 46% COS and 147 BCF gas potential.
Overall, even if the well confirm commercial success in Sand A, B & C - that will be 524 BCF & Very high CoS in these three zones.